– William Huyett Appointed to Chief Operating Officer –
– Gina Consylman Promoted to Senior Vice President, Chief Financial Officer –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced the appointment of William Huyett as chief operating officer and the promotion of Gina Consylman to senior vice president and chief financial officer.
“Strengthening our leadership team with these key appointments is critical for Ironwood as we seek to execute on our strategy to deliver rapid top-line growth and advance our innovative mid- to late-stage product candidates,” said Peter Hecht, chief executive officer at Ironwood. “Bill is a seasoned, strategic business partner who has a remarkable breadth of experience that will further strengthen our ability to build a successful and innovative company. Gina has been an invaluable finance and enterprise leader at Ironwood over the past three years and I am confident she will have an even greater impact in her expanded role. We are committed to attracting and developing leaders with great strategic judgment, absolute integrity, and an owner-oriented mindset. Bill and Gina exemplify these qualities and I am thrilled to have them as part of the executive team to drive our company forward.”
Mr. Huyett brings to Ironwood extensive experience in corporate strategy, capital allocation, finance, product development/commercialization and corporate leadership in the life sciences industry and many other business sectors. At Ironwood, he will be responsible for the company's finance, corporate strategy, corporate development, global operations, investor relations and corporate communications functions. Mr. Huyett joins Ironwood following a distinguished 30-year career at McKinsey and Company, Inc., where he served global clients in the life sciences, industrial and other technology-intensive sectors. Most recently, he has been a senior partner emeritus at McKinsey. He was a leader in the firm’s pharmaceutical and medical products and its strategy and corporate finance practices, and served on McKinsey’s Shareholder’s Council (its board of directors), serving as chair of its Finance Committee. Prior to joining McKinsey, Mr. Huyett held a variety of line management positions with Allen-Bradley (now Rockwell Automation, Inc.). Mr. Huyett serves on the board of directors of the London Stock Exchange-listed Georgia Healthcare Group PLC. He also serves on several not-for-profit boards, including The Rockefeller University, the Marine Biological Laboratory, the University of Virginia Darden School of Business and the YMCA of Greater Boston. He earned his B.S. in electronics engineering and his M.B.A. from the University of Virginia.
Ms. Consylman is a 25-year veteran in the field of corporate finance. She joined Ironwood in 2014 and currently provides oversight of the company’s finance, planning, accounting, tax, treasury and insurance functions. Prior to joining Ironwood, she was vice president, corporate controller and principal accounting officer at Analogic Corporation, served as senior director, corporate accounting at Biogen Inc., and as corporate controller at Varian Semiconductor Equipment Associates, Inc. A Certified Public Accountant, Ms. Consylman began her career in public accounting at Ernst & Young LLP. She holds a B.S. in accounting from Johnson & Wales University and a M.S. in taxation from Bentley University.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ:IRWD) is a commercial biotechnology company focused on creating medicines that make a difference for patients, building value for our fellow shareholders, and empowering our passionate team. We are commercializing two innovative primary care products: linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS‐C) or chronic idiopathic constipation (CIC), and lesinurad, which is approved for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid (sUA) levels with a medically appropriate daily dose of a xanthine oxidase inhibitor (XOI) alone. We are also advancing a pipeline of innovative product candidates in areas of significant unmet need, including uncontrolled gastroesophageal reflux disease, diabetic nephropathy, heart failure with preserved ejection fraction, achalasia and sickle cell disease. Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. For more information, please visit www.ironwoodpharma.com or www.twitter.com/ironwoodpharma; information that may be important to investors will be routinely posted in both these locations.
